Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

Caluwé A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, Longton E, Bessieres I, Vu-Bezin J, Kirova Y, Gestel DV, Desmoulins I, Ignatiadis M, Romano E, Buisseret L, Piccart M, Vandekerkhove C, Gulyban A, Poortmans P

Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial.

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.

Volders PJ, Aftimos P, Dedeurwaerdere F, Martens G, Canon JL, Beniuga G, Froyen G, Van Huysse J, De Pauw R, Prenen H, Lambin S, Decoster L, Vaeyens F, Rottey S, Van Dam PJ, Decoster L, Rutten A, Schreuer M, Loontiens S, Van der Meulen J, Mebis J, Cuppens K, Tejpar S, Vanden Bempt I, De Grève J, Schröder D, van Marcke C, Van Den Bulcke M, de Azambuja E, Punie K, Maes B

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.

Volders PJ, Aftimos P, Dedeurwaerdere F, Martens G, Canon JL, Beniuga G, Froyen G, Van Huysse J, De Pauw R, Prenen H, Lambin S, Decoster L, Vaeyens F, Rottey S, Van Dam PJ, Decoster L, Rutten A, Schreuer M, Loontiens S, Van der Meulen J, Mebis J, Cuppens K, Tejpar S, Vanden Bempt I, De Grève J, Schröder D, van Marcke C, Van Den Bulcke M, de Azambuja E, Punie K, Maes B

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer.

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm DL, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus

Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis

Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet